Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for AXIM Biotechnologies's Days Sales Outstanding or its related term are showing as below:
AXIM's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.42 * Ranked among companies with meaningful Days Sales Outstanding only.
AXIM Biotechnologies's Days Sales Outstanding
stayed the same
from Mar. 2024 (0.00) to Jun. 2025 (0.00).
AXIM Biotechnologies (OTCPK:AXIM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
AXIM Biotechnologies Days Sales Outstanding Related Terms
AXIM Biotechnologies Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM vs ZVSA, HEPA, ISCO: Days Sales Outstanding Comparison
For the Biotechnology subindustry, AXIM Biotechnologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's Days Sales Outstanding falls into.
AXIM Biotechnologies Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM) has a Days Sales Outstanding of 0.00 as of Jun. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Days Sales Outstanding too high?
AXIM Biotechnologies' current Days Sales Outstanding is 0.00.
How does AXIM Biotechnologies' Days Sales Outstanding compare to ZVSA and HEPA?
AXIM Biotechnologies' Days Sales Outstanding of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.42, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Days Sales Outstanding is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 
